Citations

Clear

1056 citation(s) found for "Sharma, D".

Persistent Trigeminal Artery as a Rare Conduit for Embolic Stroke (P1-5.012)
Bawaneh, Saif, Al-Salahat, Ali, Prajapati, Mittal, Asghar, Muhammad Roshan, Sharma, Rohan, Kapoor, Nidhi , Al‐Salahat, Ali , Prajapati, Mittal S

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000216256 Get It

Giant Cell Arteritis Masquerading as Cervical Artery Dissection (P7-5.015)
Sharma, Rishi, Klaas, James, Khan, Muhib, Oakley, Carlee, Klaas, James P. , Oakley, Carlee I.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215076 Get It

Refractory Diffuse cerebral Vasospasm Following Lobar Intracerebral Hemorrhage (P9-4.003)
Modi, Tanish , Chouhdry, Hira , Nath, Samir, Vivlamore, Emma, Sharma, Rishi, Liu, Anna, Finn, Erin, Fugate, Jennifer, Nath, Samir R. , Keser, Zafer

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000213318 Get It

PET Imaging of Osteomyelitis with [68Ga]Ga-BP
Pandey, Mukesh K., Bansal, Aditya, Sharma, Shalini, Karau, Melissa J. , Raval, Yash S. , Broski, S. M., Patel, Robin , Nathan, Mark, Lowe, Val J., Pandey, Mukesh K. , Broski, Stephen M. , Patel, Robin , Broski, Stephen M , Pandey, Mukesh K , Raval, Yash S. , Bansal, Aditya , Lowe, Val J. , Karau, Melissa

Mayo Clinic

Chemical & Biomedical Imaging | June 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1021/cbmi.6c00082 | PMID 42953237 Get It

Abstract A low-cost, easy-to-adopt noninvasive imaging modality for differentiating bacterial infection from inflammation is desirable to accurately diagnose bacterial infections. Herein, a bacteria-specific PET probe, [68Ga]Ga-BP, was developed and evaluated in rat models of foreign body-associated osteomyelitis induced by methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae and was directly compared with sterile inflammation and uninstrumented uninfected controls. [68Ga]Ga-BP-based imaging of MRSA-infected tibiae was also compared to [68Ga]Ga-citrate and [18F]FDG. After iron depletion, dynamic PET/CT imaging was performed at 15–120 min postinjection of radiotracers, followed by assessment of ex vivo biodistribution. [68Ga]Ga-BP successfully detected tibial infection and demonstrated >6-fold higher uptake in infected tibiae with all three bacterial species versus contralateral tibiae via PET imaging. [68Ga]Ga-BP outperformed [68Ga]Ga-citrate and [18F]FDG in identifying MRSA infection. [68Ga]Ga-BP represents a promising, noninvasive PET imaging agent for direct bacterial detection and bacterial infection treatment monitoring.
Outcomes of Patients With Favorable Intermediate Risk Gleason Grade Group 2 Prostate Cancer Undergoing Radical Prostatectomy in the MRI Era: Refining Active Surveillance Selection Criteria
Li, Eric V. , Ahmed, Eman E., Ahmed, Mohamed E., Wang, Michael K., Diaz‐Cobo, Julian, O'Byrne, Jamie, Cheville, John C., Shah, Paras H., Frank, Igor, Tollefson, Matthew K., Boorjian, S., Sharma, Vidit, Khanna, Abhinav, Karnes, R Jeffrey, Ahmed, Mohamed E., Diaz-Cobo, Julian, Cheville, John C. , Frank, Igor, Tollefson, Matthew K. , Sharma, Vidit , Karnes, R. Jeffrey

Mayo Clinic

The Prostate | June 8, 2026 | Volume: 86 | Issue: 12 | Pages: 1251-1257

10.1002/pros.70206 | PMID 42257571 Get It

ABSTRACT Background While guidelines state that patients with NCCN favorable intermediate risk (FIR) prostate cancer (PCa) may consider active surveillance (AS), there is a relative lack of longer term follow up data informing AS inclusion criteria of patients with Grade Group (GG) 2 prostate cancer in the MRI era. Here we evaluate patient outcomes from a MRI‐screened AS‐eligible cohort of FIR GG2 PCa receiving radical prostatectomy (RP). Methods Patients with prostate MRI, NCCN FIR GG2 PCa (PSA < 10 ng/mL, ≤ cT2a, < 50% core positivity), and no prior treatments who underwent RP from 2015 to 2023 were included from a prospectively maintained prostatectomy registry. Primary outcomes were adverse pathologic features (APF) at RP (GG3‐5, ≥ pT3a, or pN1) and biochemical recurrence (BCR). Logistic regression and Cox regression identified factors associated with APF at RP and time to BCR, respectively. Results Of 522 patients, 110 (21%) had APF at RP and 45 (9%) developed BCR with median follow up 2.4 years (IQR 1.3–2.8). On multivariable logistic regression, % Gleason pattern 4 (%GP4, %GP4 > 25% OR 2.14, 95% CI 1.28–3.58, p = 0.004) was independently associated with APF. On multivariable Cox regression for time to BCR, PSAD (HR 1.06, 95% CI 1.04–1.09, p < 0.001) and positive surgical margins (HR 1.06, 95% CI 1.09–3.78, p = 0.03) were independently associated with BCR. PIRADS, % core positivity, and specimen involvement were associated with neither APF nor BCR. Conclusions % Gleason pattern 4 > 25% and PSAD are the primary factors associated with adverse outcomes and should be considered for patients with FIR GG2 PCa considering active surveillance. PIRADS and measures of biopsy cancer volume were not associated with APF or BCR. These results may inform patient selection for active surveillance among patients with FIR GG2 PCa.
EGFR INHIBITION PROMOTES ENTEROENDOCRINE CELL DIFFERENTIATION CONTRIBUTING TO TREATMENT-ASSOCIATED DIARRHEA
Ramos, Guilherme Piovezani , Zeve, Daniel , Shepherd, Amy , Saint-Denis, Elisa, Aldefer, Olivia, Frintu, Bia, Dale, Stanley, Sharma, Karina, Mohlmann, Emma , Mannam, Prabhath , Byers, Morgan , Terzian, Jack, Ribeiro, Claudio D , Borges, Kleiton S., Carlone, Diana , Rao, M Prasada, Zeve, Daniel , Ribeiro, Claudio , Oliveira, Luiz Fernando , Borges, Kleiton Silva , O'Connell, Amy E , Carlone, Diana L , Duma, Narjust , Rao, Meenakshi , Breault, David T , Ramos, Guilherme P , Shepherd, Amy , Saint‐Denis, Elisa, Frintu, Bianca, Sharma, Karina, O’Connell, Amy E. , Florez, Narjust

Mayo Clinic

No container title available | June 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.02.729650 | PMID 42282735 Get It

ABSTRACT Enteroendocrine cells (EECs) are specialized sensors of the gastrointestinal (GI) epithelium that regulate gut function and systemic metabolism through hormone secretion. The molecular pathways directing intestinal stem cell (ISC) differentiation into EECs are incompletely understood due, in part, to their rarity. We sought to identify novel regulators of human EEC differentiation using a high-throughput screen of FDA-approved drugs and human duodenal organoids. Two epidermal growth factor receptor inhibitors (EGFRi) commonly used in cancer therapy and known to cause GI side effects, erlotinib and lapatinib, emerged as strong inducers of EEC differentiation, dramatically increasing chromogranin A (CHGA) expression compared to controls, while maintaining ISC function and organoid growth. EGFRi-treated organoids revealed robust and broad upregulation of EEC hormones, including serotonin (5HT), motilin (MLN), and somatostatin (SST), among others. In agreement with these findings, analysis of a patient cohort with lung cancer revealed an association with erlotinib use and increased circulating levels of the above EEC hormones compared to matched controls. Supporting a direct effect of EGFRi on EEC differentiation, mice treated with erlotinib demonstrated increased EEC numbers and hormones and showed EGFRi-associated diarrhea (EAD), a limiting side effect of these medications. Mechanistically, EGFRi induced upregulation of interferon (IFN) signaling targets during early ISC-to-EEC differentiation. Consistent with this, inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) attenuated EGFRi-induced EEC differentiation. These findings provide important insight into EEC differentiation that could inform treatment strategies for EAD, metabolic diseases, and GI diseases. Brief Summary Inhibition of EGFR signaling promotes human ISC-to-EEC differentiation through activation of STAT1 signaling.
Executive summary of American Radium Society Appropriate Use Criteria for the treatment of locoregionally recurrent rectal cancer
Miller, Eric D. , Jethwa, Krishan R. , Dozois, E, Jin, Zhaohui, Abood, G., Akselrod, Dmitriy, Attallah, Joseph, Codipilly, D Chamil, Anker, Christopher J., Hallemeier, Christopher L. , Kennedy, Timothy, Lee, Percy, Ling, Diane C., Newman, Neil, Sharma, Navesh, Small, William, Tchelebi, Leila, Russo, Suzanne , Akselrod, Dmitriy , Dozois, Eric, Akselrod, Dmitriy , Small, William , Jethwa, Krishan , Dozois, Eric J. , Abood, Gerard, Codipilly, Don C. , Anker, Christopher J. , Hallemeier, Christopher Leigh , Hassett, Leslie C. , Lee, Percy, Newman, Neil B. , Tchelebi, Leila T.

Mayo Clinic

Cancer | June 5, 2026 | Volume: 132 | Issue: 12 | Pages: No page available

10.1002/cncr.70464 | PMID 42246062 Get It

Abstract This literature‐based systematic review and associated guidelines provide evidence‐based paradigms for the management of locoregionally recurrent rectal cancer (LRRC). This multispecialty committee included gastrointestinal radiation and medical oncology, gastroenterology, radiology, and colorectal surgery. As is the standard, the previously described American Radium Society Appropriate Use Criteria methodology for this project was followed rigorously, with the Population, Intervention, Comparator, Outcome, Timing, and Study Design framework and Preferred Reporting Items for Systematic Reviews and Meta‐Analyses methodology to assess the evidence. RAND/University of California Los Angeles consensus methodology (modified Delphi) was used to rate the appropriateness of treatment options. Published between January 1, 2013, and July 16, 2025, 116 peer‐reviewed trials provided the evidence: 10 were well‐designed randomized phase 2/3 trials, 29 were moderately well designed trials that accounted for most common biases (matched cohort and phase 2), 76 trials had design limitations (retrospective), and one was a meta‐analysis. Clinical cases were created as examples to illustrate current acceptable management of LRRC. Treatment and prognosis are influenced by prior therapy and the site(s) and extent of LRRC. The ability to achieve a margin‐negative surgical resection is the ultimate determinant of survival and local control. Preoperative systemic therapy, radiation therapy, or a combination of the two can facilitate tumor downsizing and improve the likelihood of a margin‐negative resection. An individualized multidisciplinary approach is required to ensure the best outcome. Although this review does not suggest a major alteration of current practice, it provides reassuring evidence of the importance of combined‐modality therapy.
Comparative Post-Transplant Outcomes in Alcohol-Related Liver Disease and Non-Alcohol Steatohepatitis: A Multicenter Propensity-Matched Study
Khan, Sajjad Ahmed , Dhali, Arkadeep , Bharadwaj, Hareesha Rishab , Alsakarneh, Saqr, Mohamed, Islam, Sultany, Abdullah , Singh, Sahib, Ali, Hassam, Dahiya, Dushyant Singh , Sharma, Ashish , Sultany, Abdullah , Dahiya, Dushyant Singh , Bharadwaj, Hareesha Rishab , Sharma, Ashish , Alsakarneh, Saqr , Mohamed, Islam , Ali, Hassam

Mayo Clinic

Medical Sciences | June 1, 2026 | Volume: 14 | Issue: 2 | Pages: 286

10.3390/medsci14020286 | PMID 42346825 Get It

Background: Liver transplantation (LT) remains the definitive treatment for end-stage liver disease; however, post-LT outcomes may differ depending on underlying disease etiology. Our study aimed to compare post-LT outcomes between alcoholic and non-alcoholic steatohepatitis (NASH)-related liver transplant recipients in the United States. Methods: A retrospective cohort study was conducted using the TriNetX Research Network. Adult liver transplant recipients (≥18 years) were categorized into two mutually exclusive cohorts: alcoholic liver disease and NASH-related liver disease. Propensity score matching (1:1) was performed to balance baseline characteristics. Clinical outcomes were assessed. Comparative analyses included risk ratios, risk differences, odds ratios, Kaplan–Meier survival analysis, and hazard ratios with log-rank testing. Results: Compared with NASH recipients, alcoholic LT recipients had a significantly higher risk of rejection (14.5% vs. 12.1%; RR 1.195, 95% CI 1.076–1.327; p = 0.001) and hepatic encephalopathy (14.3% vs. 8.3%; RR 1.720, 95% CI 1.526–1.938; p < 0.001). Acute kidney injury was also more frequent in the alcoholic cohort (47.3% vs. 43.6%; RR 1.084, 95% CI 1.036–1.133; p < 0.001). In contrast, sepsis (15.6% vs. 18.0%; RR 0.869, 95% CI 0.794–0.952; p = 0.003) and CKD (46.1% vs. 51.1%; RR 0.901, 95% CI 0.863–0.939; p < 0.001) occurred less frequently in alcoholic LT patients. No significant differences were observed for liver transplant failure or ascites. Kaplan–Meier analyses demonstrated significantly lower rejection-free survival (HR 1.241, p < 0.001), higher hepatic encephalopathy (HR 1.808, p < 0.001), increased AKI risk (HR 1.150, p < 0.001) and higher all-cause mortality in the alcoholic cohort (HR 1.106, p = 0.031). Conclusions: In this large real-world matched cohort study, alcoholic LT recipients demonstrated higher risks of complications and all-cause mortality compared with NASH LT recipients.
Fecal Immunochemical Test and Multitarget Stool DNA Testing for Colorectal Cancer Screening in Real-World Practice: A Literature Review
Tiwari, Angad , Ray, Ishita , Paladiya, Ruchir, Kumar, Harendra , Sidhu, Sukhmani, Haldule, Saloni , Bharadwaj, Hareesha Rishab , Alsakarneh, Saqr, Gangwani, Manesh Kumar , Ali, Hassam, Dahiya, Dushyant Singh , Sharma, Ashish , Tiwari, Angad , Ray, Ishita , Paladiya, Ruchir , Kumar, Harendra , Sidhu, Sukhmani , Bharadwaj, Hareesha Rishab , Dahiya, Dushyant Singh , Sharma, Ashish , Alsakarneh, Saqr , Ali, Hassam

Mayo Clinic

Journal of Clinical Medicine | May 29, 2026 | Volume: 15 | Issue: 11 | Pages: 4219

10.3390/jcm15114219 | PMID 42279081 Get It

Colorectal cancer (CRC) is responsible for a high cancer burden and a high number of deaths all over the world, although effective screening can make it preventable to a significant extent. Stool-based tests, such as the fecal immunochemical test (FIT) and multitarget stool DNA (mt-sDNA) testing, are gaining considerable popularity as non-invasive procedures that can be a replacement for colonoscopies for people at an average risk for colon cancer. Despite evidence from several randomized controlled trials supporting the use of these tests for colorectal cancer screening, their external validity in a real-world setting is influenced by many factors such as adherence, timely follow-up post testing, the healthcare cost burden, accessibility and the capacity of the health system. In this article, we have performed an extensive narrative literature review of research published between 2020 and 2025 comparing FIT and the mt-sDNA test with reference to diagnostic accuracy, cost-effectiveness, adherence and outcomes of implementation. We discuss the issues of sensitivity and specificity, look at post-test requirements for colonoscopy and check if there is any discrimination in healthcare. These findings suggest that FIT and mt-sDNA tests should not be considered competing technologies but rather complementary screening methods, with their overall effectiveness contingent upon appropriate patient selection and widespread system-level implementation. It is crucial to combine strategic test selection with a robust follow-up infrastructure to ensure that the entire population benefits from the CRC prevention program.
A phase 1, first-in-human (FIH), dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 T-cell engager in participants with advanced or metastatic microsatellite-stable (MSS)/
Spira, Alexander I., Sommerhalder, David , Winterhall, Annie, Buchholz, Tonia J., Bateman, Tarah, rock, Dan, Alese, Olatunji B., Berz, David, Fakih, Marwan , Hecht, J. Randolph, Oh, David Y. , Sharma, Manish R. , Wu, Christina, Spira, Alexander I. , Kugler, David G. , Alese, Olatunji B. , Berz, David , Nagorsen, Dirk

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps3678 Get It

TPS3678 Background: Advanced and metastatic colorectal cancer (CRC) remains an area of significant unmet clinical need, particularly for patients with MSS/MSI-L tumors. In recent years, there have been several advancements in the treatment of solid tumors with T cell engagers. Our ATLAS scRNA-seq based discovery platform identified LY6G6D as a highly-specific tumor-associated antigen in advanced and metastatic CRC. CBI-1214, a CD3 bispecific T cell engager targeting LY6G6D with potent in vitro and in vivo activity even at low LY6G6D expression levels of ~300 copies/cell ( Yigit B et al, AACR 2025 ), is being developed for the treatment of patients with advanced or metastatic MSS/MSI-L CRC. Methods: This ongoing, open-label FIH study (CBI-1214-001) is being conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of CBI-1214 and to determine the maximum tolerated dose (MTD) and/or optimal biological dose (OBD) in participants with advanced or metastatic MSS/MSI-L CRC who have exhausted at least one prior line of systemic treatment and do not qualify for available targeted treatment options for actionable genomic alterations. Additional eligibility criteria include: at least 18 years of age, measurable disease (as defined by RECIST v1.1), available archival tumor tissue sample or a fresh tumor sample, ECOG PS 0 or 1, as well as adequate hematologic and organ functions. Patients whose CRC tumor tissues have been identified as dMMR or MSI-H are excluded. The study is conducted in two parts: Part 1 dose escalation, which starts with Part 1a as accelerated dose escalation, followed by Part 1b escalation, which is based on a modified toxicity probability interval (mTPI-2) design, and Part 2, which is designed as a randomized dose optimization study to select the final recommended phase 2 dose (RP2D). For both parts of the study, the study intervention is administered as monotherapy, given as an intravenous (IV) infusion, in 21-day treatment cycles, with a step-up option. After an up-to-28-day screening period, eligible patients receive study medication and are followed for their entire treatment period plus a follow-up period of approximately 90 days. The study is open for recruitment in the United States (NCT07321106). Clinical trial information: NCT07321106 .